Categories
Change Password!
Reset Password!
Treatment with bDMARDs should be initiated in patients showing inadequate response to CsDMARDs. Barcitinib as monotherapy as well as in combination with CsDMARDs was found effective in treating RA.
Baricitinib with advantages like
oral administration, rapidity of action, efficacy in monotherapy and over
adalimumab in one study and non-immunization found efficacious in rheumatoid
arthritis (RA) treatment. In the past decades, improvement has been seen in the
outcome for rheumatoid arthritis patients, but appropriate control of disease
cannot be achieved in a substantial proportion of patients. Newly available
drugs having the novel mechanism of action could be an added value to the
current armamentarium.
This review concentrate on the pharmacodynamics and pharmacokinetics of
baricitinib. Moreover, the article summarizes and comments on the drug's
efficacy and safety profile in RA patients.
Baricitinib is available for oral administration. It is a targeted synthetic JAK1 and JAK2 inhibitor. Baricitinib either as monotherapy, or is given in combination with conventional synthetic (cs) DMARDs, has revealed its efficacy with an acceptable safety profile in early active RA naive to DMARDs, and active RA with an inadequate response to csDMARDs and/or biologic (b)DMARDs.
The future status of baricitinib for the management of RA patients will depend
on several factors. Additional long-term safety data will influence prescribing
decisions.
Expert Opin Pharmacother. 2017 Jul 24
Efficacy of baricitinib in the treatment of rheumatoid arthritis
Richez C, Truchetet ME et. al.
Comments (0)